COVID-19

Excerpt from the Press Release: PARIS and LEXINGTON, Mass., March 12, 2021 (GLOBE NEWSWIRE) — Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the…

Excerpt from the Press Release: SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized…

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the Company’s next generation COVID-19 vaccine candidate. “We are pleased to begin this Phase 1 study of our…

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR)grant for $255,908 to conduct research and development (R&D) work onrapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has…

Excerpt from the Press Release: PRINCETON, N.J., March 4, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating rapid-onset,…

Excerpt from the Article: It’s rare for current events to inform the work of scientists as acutely as during a pandemic. In February 2020, a team of scientists from the international initiative of the Human Cell Atlas, including scientists at the Broad Institute of MIT and Harvard, sifted through a dataset on healthy human cells…

Excerpt from the Article: As the COVID-19 pandemic enters its second year, scientists are still working to understand how the SARS-CoV-2 strain evolved, and how it became so much more dangerous than other coronaviruses, which humans have been living alongside for millennia. Virologists and epidemiologists worldwide have speculated for months that a protein called ORF8…

Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This…

Excerpt from the Article: MRI scans reveal myocarditis, scarring, infarction, and ischemia in recovered patients with elevated troponin levels. Roughly 50 percent of patients who recover after being hospitalized with severe COVID-19 suffer heart damage. MRI scans, conducted at least one month post-discharge, show patients who have elevated levels of troponin show evidence of heart…

Excerpt from the Press Release: Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School…